Board

Fredrik Sjövall, Chairman

Born: 1980
Appointed: April 5, 2017.
Qualifications: M.Sc. Automation Engineering, Master’s Degree in Business Development. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.
Experience: Fredrik has got 20 years of experience from management positions in the life science industry. Previously the CEO of Inhalation Sciences, Hemcheck, Lipopeptide and PharmaSurgics.
Current roles: Currently Chairman at the public companies Lipidor and Monivent. Also Chairman of Emollivet and board member of Phargentis.
Ownership: 178 000 shares and 42 200 warrants

Mikaela Bruhammar

Born: 1976
Appointed: 20 Maj 2019.
Qualifications: MSc Molecular Biology. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.
Experience: Mikaela has 20 years of experience working at major global life-science companies. She has held several strategic commercial roles and senior management positions in the Nordic region, on global and HQ level. During 1999-2008, various commercial roles with MSD Sweden AB, 2008-2012 local marketing and strategic roles with AstraZeneca Sweden and Nordic-Baltic. From 2012 to 2015 she was the Global Head of Astra Zeneca’s Vaccine Franchise, from 2015-2019 Vice President of Nordic-Baltic Business Unit in Respiratory, Inflammation and Autoimmune disease (RIA). Since Aug 2019 Head of Nordic Region for Real World Evidence at IQVIA.
Ownership: 9 000 shares and 42 200 warrants

Andreas Pettersson Rohman

Born: 1980.
Appointed: April 27 2021.
Qualifications: MSc. and BSc. Industrial Engineering and Management, Chalmers University of Technology. MSc. Advanced Finance, School of Business, Economics and Law, Gothenburg University. BSc National Economics, School of Business, Economics and Law, Gothenburg University. Independent of major shareholders of Ziccum.
Experience: Andreas has extensive experience from strategy development as well as supportive debt and equity financing. He currently serves as Senior Director and leading the Corporate Finance department at Northvolt and previously worked as an Investment Professional at EQT within the Private Equity business line and prior to that at Goldman Sachs International in London within the Investment Banking Division.
He has also served as Member of the Board at the BlueStep Bank.
Current roleS: Vice president corporate finance and investor relations Northvolt AB.
Ownership: 39 333 shares and 42 200 warrants.

Martina Banyay

Born: 1967
Appointed: April 28, 2022
Qualifications: Ph.D. Biophysics. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum.
Experience: 20 years of experience from executive roles in fast-growing Life Science companies, with a focus on management, strategy, business- and team development. Previous roles include Chief Operating Officer & Chief Digital Officer at Atlas Antibodies, a Swedish biotech company active in the field of advanced research reagents, Manager at Sidec AB, a contract research company with global pharma and biotech clients, and Business development consultant at Banyay Consulting AB.
Current roles: Chief Executive Officer at VivoLogica AB.
Ownership: 3 000 shares and 33 000 warrants

Dr Christina Herder

Born: 1961
Appointed: April 28, 2022
Qualifications: Technical doctor in physical chemistry from KTH and an MBA from Stockholm University. Independent of Ziccum and its senior management. Independent of major shareholders of Ziccum. She was previously CEO for Modus Therapeutics and have been on senior positions on Swedish Orphan Biovitrum AB (Sobi) and Biovitrum.
Experience: More than 25 years of experience of drug- and business development withing the pharma industry.
Current roles:Executive Vice President, Strategic Business Development at Medivir AB. She is also a board member in PCI Biotech Holding, Idogen AB and Elicera Therapeutics.
Ownership: No shares and 33 000 warrants